Response to Anti-Pd1 Therapy With Nivolumab in Metastatic Sarcomas

Clinical Sarcoma Research - United Kingdom
doi 10.1186/s13569-016-0064-0
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Response and Outcomes After Anti-Ctla4 Versus Anti-Pd1 Combined With Stereotactic Body Radiation Therapy for Metastatic Non-Small Cell Lung Cancer: Retrospective Analysis of Two Single-Institution Prospective Trials

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Targeting Tumor-Intrinsic Hexosamine Biosynthesis Sensitizes Pancreatic Cancer to Anti-Pd1 Therapy

Journal of Clinical Investigation
Medicine
2019English

Response to Nivolumab in Metastatic Collecting Duct Carcinoma Expressing PD‑L1: A Case Report

Molecular and Clinical Oncology
Cancer ResearchOncology
2017English

Targeting PIM Kinase With PD1 Inhibition Improves Immunotherapeutic Anti-Tumor T Cell Response

Clinical Cancer Research
Cancer ResearchOncology
2019English

Tumoral EHF Predicts the Efficacy of Anti-Pd1 Therapy in Pancreatic Ductal Adenocarcinoma

Journal of Experimental Medicine
MedicineAllergyImmunology
2019English

Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab

Clinical Genitourinary Cancer
OncologyUrology
2017English

Anti-Pd1 in the Wonder-Gut-Land

Cell Research
Cell BiologyMolecular Biology
2018English

Photodynamic Therapy With Acridine Orange in Musculoskeletal Sarcomas

The Journal of Bone and Joint Surgery. British volume
2010English

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy